MeiraGTx (MGTX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate ...

The AAV-GAD bridging study met the primary endpoint of safety and tolerability, and showed early promise in Parkinson’s ...

MeiraGTx is looking to march its Parkinson’s disease treatment forward into phase 3 after the gene therapy improved motor ...

Alec Stranahan, an analyst from Bank of America Securities, maintained the Buy rating on Meiragtx Holdings (MGTX – Research Report). The ...

MeiraGTx Holdings (MGTX) stock gains in premarket trading after positive trial results for the company's AAV-GAD gene therapy ...

Exciting results for MeiraGTx Holdings plc's GAD gene therapy for Parkinson's Disease, with promising phase 1/2 data and ...

According to MeiraGTx, AAV-GAD is designed to reprogramme dysfunctional circuits in the Parkinson's brain through the local production of GABA, a neurotransmitter that can help restore more normal ...

On Tuesday, MeiraGTx Holdings PLC (MGTX) stock saw a modest uptick, ending the day at $5.33 which represents a slight increase of $0.69 or 14.87% from the prior close of $4.64. The stock opened at $5.

US clinical-stage genetic meds company MeiraGTx Holdings has released positive top-line data from its clinical bridging study ...

MeiraGTx unveiled results from a small dataset for its Parkinson’s disease gene therapy on Tuesday morning, causing its ...

伦敦和纽约 - 临床阶段基因医学公司MeiraGTx Holdings plc (NASDAQ:MGTX)宣布其最新临床试验MGT-GAD-025取得令人鼓舞的结果。该试验旨在治疗帕金森氏症,达到了主要的安全性和耐受性目标,同时在特发性帕金森氏症患者的关键疗效终点上也显示出显著改善。

The company said the latest positive safety, tolerability, and efficacy data will underpin discussions with regulators in the US, Europe, and Japan.